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 Abstract 23 
OBJECTIVES: To conduct a population pharmacokinetic analysis of continuous infusion (CI) 24 
ceftazidime in a retrospective cohort of pediatric HSCT patients who were empirically treated for 25 
febrile neutropenia (FN) and who underwent therapeutic drug monitoring of steady-state 26 
concentrations (Css) for optimization of drug exposure.  27 
METHODS: Non-parametric approach with Pmetrics was used for pharmacokinetic analysis and 28 
covariate evaluation. Monte Carlo simulations were performed to calculate the PTA of the 29 
pharmacodynamic determinant of efficacy (Css/MIC ≥ 4) against Pseudomonas aeruginosa with CI 30 
ceftazidime dosages of 1 to 6 g daily. Css safety threshold was arbitrarily placed at 100 mg/L and 31 
advisable dosages were used. 32 
RESULTS: A total of 46 patients with 70 ceftazidime Css were included. Estimated glomerular 33 
filtration rate (eGFR) and body surface area (BSA) were the covariates associated with drug 34 
clearance. At the EUCAST clinical breakpoint of 8 mg/L, simulations showed that CI ceftazidime 35 
dosages of 4-6 g daily attained optimal PTAs (>90%) across most of 16 different clinical scenarios 36 
based on four classes of  eGFR (50-145, 145.1-200, 200.1-286, 286.1-422 mL/min/1.73 m2) and BSA 37 
(0.30-0.64, 0.65-0.88, 0.89-1.34, 1.35-1.84 m2). In patients with BSA 0.30-0.64 m2 and eGFR ≤ 200 38 
mL/min/1.73 m2 the advisable dose of 3 g daily allowed only suboptimal PTAs (<75%). The 39 
cumulative fraction of response against MIC distribution of Pseudomonas aeruginosa was > 87%.  40 
CONCLUSIONS: CI ceftazidime dosages ranging from 3 and 6 g daily according to different classes 41 
of eGFR and BSA may allow optimized empirical treatment of Pseudomonas aeruginosa infections 42 
in pediatric HSCT patients with FN. 43 
44 
 Introduction 45 
Febrile neutropenia (FN) is one of the most common complications in children who receive 46 
induction chemotherapy and undergo HSCT.1 Bacteremia accounts for around 30% of bacterial 47 
infections in children with high-risk FN,2 and Gram-negative bacteria cause 53.9-65% of all reported 48 
episodes.3, 4 Pseudomonas aeruginosa is one of the most common etiological agents, together with 49 
Klebsiella pneumoniae and Escherichia coli.3, 5 50 
Pseudomonas aeruginosa bacteremia is associated with high fatality rates in children,6 and in 51 
high-risk FN patients may be as high as 52%.7  Multidrug-resistant strains are common.8  Current 52 
guidelines of the American Society of Clinical Oncology recommend monotherapy with an anti-53 
pseudomonal beta-lactam as empirical therapy in pediatric patients with high-risk FN.9 A second 54 
Gram-negative agent, such as an aminoglycoside, is reserved for patients who are clinically unstable, 55 
when resistant infection is suspected or for patients in centers with high prevalence of resistant 56 
pathogens.9  57 
Ceftazidime is an antipseudomonal third-generation cephalosporin that is widely used in 58 
patients with FN.10  Ceftazidime has a low potential for drug-drug interactions, is almost completely 59 
renally eliminated (80 to 90%) and has low plasma protein binding (approximately 10%).11, 12 It may 60 
have a more favorable safety profile compared to other anti-pseudomonal cephalosporins, with a 61 
lower risk for neurotoxicity.13  62 
 Beta-lactams are often administered intermittently. However, administration by extended or 63 
continuous infusion (CI) may optimize the time free plasma drug concentrations are above the MIC 64 
(fT>MIC) and therefore maximizing time-dependent antibacterial activity.14 This approach may be 65 
helpful especially in critically ill patients and/or in presence of pathogens with borderline 66 
susceptibility. There is growing evidence that administering beta-lactams by prolonged or CI may 67 
improve clinical efficacy in patients with sepsis.15, 16 A recent meta-analysis showed that prolonged 68 
infusion of antipseudomonal beta-lactams for the treatment of patients with sepsis was associated 69 
with significantly lower mortality than intermittent infusion.16  70 
 The use of prolonged or CI of beta-lactams is increasing even among the pediatric  71 
population,17 including for ceftazidime.18-21  The aim of this study was to conduct a population 72 
pharmacokinetic analysis in a cohort of pediatric HSCT children with FN who were empirically 73 
treated with CI ceftazidime and to identify dosing regimens for maximizing empirical treatment of 74 
Pseudomonas aeruginosa infections.        75 
 76 
 77 
 78 
 79 
  80 
 Methods 81 
Study design 82 
This retrospective study included a cohort of pediatric patients who underwent HSCT at the 83 
Institute for Maternal and Child Health IRCSS Burlo Garofolo, Trieste, Italy, and who received CI 84 
ceftazidime for the empirical treatment of high risk FN in the period between June 2012 and 85 
December 2017.  86 
Ceftazidime treatment was started with a loading dose (LD) of 60-100 mg/kg infused in 1 87 
hour, which was immediately followed by a maintenance dose (MD) of 100-200 mg/kg daily 88 
administered by CI.  Dosage adjustments were guided by real-time therapeutic drug monitoring 89 
(TDM) of ceftazidime steady-state plasma concentrations (Css), which were assessed after at least 2 90 
days from starting therapy. Drug dosages were adjusted using a linear scaling with a minimum dose 91 
modification of 500 mg. The desired range of ceftazidime plasma Css was set between 32 and 64 92 
mg/L. The rationale was that of maximizing empirical treatment against P. aeruginosa by achieving 93 
a Css between 4-fold and 8-fold the EUCAST clinical breakpoint of ceftazidime versus P. aeruginosa 94 
which is 8 mg/L.22 This strategy may be especially helpful when in presence of severe infections.23, 95 
24 96 
TDM of ceftazidime was provided by the Institute of Clinical Pharmacology, Santa Maria 97 
della Misericordia University Hospital, Udine, Italy. TDM-guided clinical pharmacological advices 98 
for personalized ceftazidime dosages were usually provided to the attending clinicians within the 99 
same day of the analysis. Ceftazidime concentrations were analyzed by means of a validated HPLC 100 
with UV detection as described elsewhere.25 Precision and accuracy were assessed by performing 101 
replicate analysis of quality control samples against calibration standards. Intra- and inter-assay 102 
coefficient of variation were < 10%. The lower limit of detection was 0.1 mg/L.  103 
The following demographic and clinical data were retrieved from patient clinical records: age, 104 
gender, weight, height, body surface area (BSA), duration of therapy, date of HSCT and type of 105 
underlying oncological or hematological disease and co-treatment with other antimicrobials. Baseline 106 
 and end-of-treatment data on serum concentrations of ALT, AST and total bilirubin as well as sign 107 
and symptoms of neurotoxicity potentially related with ceftazidime therapy were also collected. 108 
Serum creatinine was measured at each TDM instances and estimated glomerular filtration rate 109 
(eGFR) was calculated by means of the Schwartz formula.26 BSA was calculated by means of the 110 
Mosteller formula.27   111 
Clinical outcome to ceftazidime treatment was classified as cured, unchanged or failed 112 
according the response  assessed by the attending physician. A patient was classified as cured in the 113 
presence of a decrease of C-RP and body temperature and of an improvement of clinical conditions. 114 
A patient was classified as unchanged or failed after three days of ceftazidime treatment whenever 115 
CRP, body temperature or clinical conditions did not improve or deteriorate, respectively. In these 116 
cases, antimicrobial therapy was escalated to meropenem.  117 
 118 
Population pharmacokinetic modelling 119 
 One and two-compartment models with zero-order input and first-order elimination from the 120 
central compartment were constructed and fitted to the observed concentrations using the non-121 
parametric grid (NPAG) approach contained in the Pmetrics package of R (Laboratory of Applied 122 
Pharmacokinetics, Los Angeles, CA, USA).28 Estimates of the assay error were included in the 123 
modelling process as a four-term polynomial equation, which relates drug concentrations to the 124 
standard deviations of the observations. Both gamma and lambda were tested in the error model for 125 
accounting for process error. Individual pharmacokinetic parameters (total CL, volume of distribution 126 
of the central compartment [V], inter-compartment transfer rate constant from the central to the 127 
peripheral compartment [kcp] and vice versa [kpc]) were estimated by a maximum a posteriori (MAP) 128 
probability Bayesian technique.    129 
 Initially, a base model without covariates was developed and fitted to the data.  Subsequently, 130 
the relationship between Bayesian estimates of CL and V for each patient and clinically relevant 131 
covariates (age, weight, height, sex, BSA, eGFR, time from HSCT, presence of acute leukemia) was 132 
 assessed. A forward-backward selection process for covariate inclusion was adopted by using the 133 
Pmetrics “PMstep” function. A final multivariate model including all the significant covariates was 134 
then developed and refitted to the data. The performance of the pharmacokinetic models was assessed 135 
by means of visual inspection of the observed-predicted plot, the coefficient of determination of the 136 
linear regression of the observed-predicted values and of the likelihood ratio test. Differences in the 137 
objective function value (OFV) greater than 3.84 between each pharmacokinetic model and the base 138 
model (p < 0.05), coupled with evaluation of the Akaike information criteria (AIC), were considered 139 
as statistically significant additions to the model. Model performance was evaluated by means of 140 
normalized prediction distribution errors (NPDEs), which is a metric design to allow evaluation of 141 
non-linear mixed-effect models.  142 
 143 
Monte Carlo simulation analysis for determining the probability of target attainment for 144 
empirical treatment against Pseudomonas aeruginosa  145 
1000-subject Monte Carlo simulations based on the final model were performed for each of 146 
six incremental dosing regimens of CI ceftazidime (1g q24h, 2g q24h, 3g q24h, 4g q24h, 5g q24h and 147 
6g q24h) for determining the PTA for maximized empirical treatment against Pseudomonas 148 
aeruginosa. Variability of the continuous covariates included in the final model was assessed by 149 
splitting each covariate  distribution, as observed in our population, into four categories corresponding 150 
to four quartiles (0-25th percentile, 25th-50th percentile, 50th-75th percentile, 75th-100th percentile).   151 
Ceftazidime Css were simulated at 48 h by means of the Pmetrics simulation engine. The 152 
desired pharmacodynamic target was Css/MIC ≥ 4 at the EUCAST clinical breakpoint of 8 mg/L. 153 
PTAs were considered acceptable when ≥ 80%, and optimal when ≥ 90%.29  154 
For safety purposes, an upper threshold for simulated ceftazidime Css was placed at 100 mg/L 155 
(potential toxicity threshold). The rationale was based on previous studies suggesting that this choice 156 
might be helpful in minimizing the risk of neurotoxicity with high-dose CI beta-lactams.18, 30 Dosing 157 
 regimens associated with less than 10% of probability of exceeding this threshold were considered as 158 
advisable for the empirical treatment against Pseudomonas aeruginosa.  159 
The cumulative fractions of response (CFR) achievable with the different CI ceftazidime 160 
dosing regimens were tested against the MIC distribution of Pseudomonas aeruginosa as reported by 161 
EUCAST31 (n=32276 isolates) as well as against the MIC distribution of Pseudomonas aeruginosa 162 
collected at our center in the period January - June 2018 (n=179 isolates). The CFR was calculated 163 
from the PTA obtained from the Monte Carlo simulation analysis. Computation of the risk-to-benefit 164 
ratios defined as the ratio of the probability of potential toxicity over the CFR observed for the 165 
ceftazidime dosages against Pseudomonas aeruginosa was also provided.  166 
 167 
Etichs 168 
The study was approved by the Ethics Review Board of the Institute for Maternal and Child 169 
Health IRCSS Burlo Garofolo, Trieste, Italy. The approval reference number was RC 26/18, Linea 2.  170 
Informed written consent was waived due to the retrospective nature of the investigation.  171 
 172 
Statistical analysis 173 
 The Kolmogorov-Smirnov test was used to assess normal or non-normal distribution of 174 
patient’s data.  Accordingly, data were summarized as mean ± standard deviation or median with 175 
25th-75th percentiles, in the descriptive statistics. Differences between continuous variables were 176 
assessed using the Student t test or Mann-Whitney test depending on whether the data were normally 177 
distributed.  All statistical analysis and plotting were performed with R, version 3.4.4 (R foundation 178 
for Statistical Computing, Vienna, Austria).   179 
  180 
 Results 181 
Patient characteristics 182 
A total of 46 HSCT children with high risk FN were included in this study. Table 1 183 
summarizes patient clinical and demographic characteristics. The median (min-max range) age, BSA 184 
and eGFR were 7.5 years (0.5-16), 0.88 m2 (0.34-1.84) and 200.0 mL/min/1.73 m2 (50.0-422.6), 185 
respectively. 186 
Most of the patients (32/46, 69.6%) had hematological malignancies, with acute lymphatic 187 
leukemia being the most frequent (22/46, 47.8%). Median (IQR) neutrophil count at start of therapy 188 
was 0.0 (0.0 – 10) cells/mm3 with a median duration of neutropenia of 16 (13 – 19) days. 189 
Ceftazidime treatment was started after a median (IQR) of 6.0 (1.0 – 11.75) days from HSCT 190 
and had median (IQR) duration of 10.5 (7.0 – 16.0) days. The median (IQR) loading and maintenance 191 
doses of ceftazidime were of 80.0 (49.2-139.7) mg/kg and of 145.9 (128.3 – 171.3) mg/kg daily. 192 
Median (IQR) total maintenance dose was of 3.5 (2.5 – 5.0) g/day by CI, with a min-max range of 1 193 
– 10 g/day. First TDM assessment occurred after a median (IQR) of 3.0 (2.0 – 5.75) days from 194 
starting therapy and in that occasion the observed Css were ≤ 8 mg/L (Css/MIC≤1) and ≤ 32 mg/L 195 
(Css/MIC≤4) in 1 and in 9 patients, respectively.  Among those patients who had ≥ 2 TDM 196 
assessments over time (17/46, 36.9%), the ceftazidime dosage was adjusted in 12 cases. All patients 197 
received antibiotic combination therapy. Amikacin (38/46, 82.6%) was the most frequently used 198 
followed by glycopeptides, either vancomycin or teicoplanin (33/46, 71.7%). 199 
No patient had signs of hepatic toxicity. Median baseline versus end of treatment levels were 200 
21.0 versus 27.0 IU for AST (p = 0.261), 21.0 versus 21.5 IU for ALT (p = 0.437) and 0.62 versus 201 
0.64 mg/dL (p = 0.791) for bilirubin. Similarly, no episodes of ceftazidime-related neurotoxicity 202 
were reported. Cure was observed in 39% of patients (18/46), whereas clinical conditions did not 203 
improve in 54.3% (25/46) of cases and an escalation to meropenem was deemed necessary. Three 204 
patients died from complications directly related to their hematological malignancies.   205 
 206 
 Population pharmacokinetic modeling 207 
A total of 70 plasma ceftazidime Css samples were included in the population pharmacokinetic 208 
model.  A two-compartment model performed better than a one-compartment model (OFV of 612.9 209 
versus 620.2 and AIC of 622.7 versus 626.6, R2 of 0.88 versus 0.82, for the two- and the one-210 
compartment model, respectively). An additive lambda term of 4.87 was estimated and included in 211 
the error model.  Covariates that improved the fit of the model to the data were the patient’s BSA and 212 
eGFR (when applied to ceftazidime CL), and the patient’s height (when applied to ceftazidime V). 213 
After the inclusion of these covariates, the OFV and AIC furtherly improved to 578.3 and 596.6, 214 
respectively.  The final structural model was as follows:  215 
CL (L/h) = θ1 • (
𝐵𝑆𝐴
0.88
)θ2 • (
𝑒𝐺𝐹𝑅
200.5
)θ3  216 
V (L) = θ4 • (
ℎ𝑒𝑖𝑔ℎ𝑡
120
)θ5  217 
where, BSA, eGFR and height represent the values of body surface area, estimated glomerular 218 
filtration rate and patients’ height, respectively. Each covariate was normalized by the median of its 219 
relative distribution as observed in the population. The performance of the different models built for 220 
covariate analysis is reported in Table S1 of the Supplementary Material.     221 
There was a good fit of the final model to the observed data (Figure 1).  A linear regression 222 
of the observed-predicted values before and after the Bayesian step had an R2 value of 0.216 and of  223 
0.877, respectively, with minimal bias and imprecision. The parameter estimates of ceftazidime for 224 
the final population Bayesian pharmacokinetic model are summarized in Table 2. The median 225 
estimates of the final multivariate model were 3.18 L/h (1.78 – 4.79 L/h) for CL and 26.45 L (24.41 226 
– 33.61 L) for V.  Distribution of NPDEs followed a gaussian distribution and no trends were evident 227 
in the scatterplot of NPDE versus time and versus predicted outcome (Supplementary Figure S1).   228 
 229 
Monte Carlo simulation 230 
 A total of ninety-six Monte Carlo simulations were conducted in order to test six incremental 231 
dosing regimens of CI ceftazidime (ranging from 1 g q 24h to 6 g q 24h) across sixteen different 232 
clinical scenarios. These clinical scenarios resulted from the combination of four classes of BSA 233 
(0.30-0.64, 0.65-0.88, 0.89-1.34 and 1.35-1.88 m2) and of four classes of eGFR (50-145, 145.1-200, 234 
200.1-286 and 286.1-422 mL/min/1.73 m2).  235 
Figure 2 shows the CI ceftazidime dosages needed for attaining the desired Css/MIC ratio ≥ 4 236 
at the EUCAST clinical breakpoint against Pseudomonas aeruginosa (8 mg/L) in the different clinical 237 
scenarios. In patients with eGFR of 50-145 mL/min/1.73 m2, ceftazidime dosages ranged between 4 238 
g q24h CI for BSA ≤ 1.34 m2 and 5 g q24h CI for BSA > 1.34 m2. Likewise, in patients with eGFR 239 
of 145.1-200 mL/min/1.73 m2, ceftazidime dosages were 4 g q24h CI for BSA ≤ 0.88, and 5 g q24h 240 
CI for BSA > 0.88 m2. In patients with eGFR of 200.1-286 mL/min/1.73 m2 and 286.1-422 241 
mL/min/1.73 m2, ceftazidime dosages were 4 g q24h CI for BSA ≤ 0.64, 5 g q24h CI for BSA between 242 
0.65 and 1.34 m2, and 6 g q24h CI for BSA > 1.34 m2.  243 
Table S2 summarizes the PTA associated with three different  weight-based dosing regimens 244 
of ceftazidime (50 mg/kg LD over 1h followed by an MD of 100 mg/kg/day by CI, 75 mg/kg LD 245 
over 1 h followed by an MD of 150 mg/kg/day by CI, 100 mg/kg LD ovder 1h followed by an MD 246 
of 200 mg/kg/day by CI) in children weighting < 40 kg and having eGFR of  50-422 mL/min/1.73 247 
m2. Optimal PTAs were attained at an MIC of 8 mg/L only with the highest dosing regimen tested.  248 
The percentages of probability of achieving ceftazidime Css above the safety threshold of 100 249 
mg/L in the different clinical scenarios are reported in Table 3. For safety purposes, CI ceftazidime 250 
dosages should not exceed 3g q24h CI in patients with BSA 0.30-0.64 m2 and eGFR 50-200 251 
mL/min/1.73 m2, 4g q24h CI in those with BSA 0.30-0.64 m2  and eGFR 200.1-422 mL/min/1.73 m2 252 
and in those with BSA 0.65-0.88 m2 and eGFR 50-145 mL/min/1.73 m2, and 5g q24h CI in those 253 
with BSA 0.30-0.64 m2 and eGFR 145.1-200 mL/min/1.73 m2.  254 
Table 4 summarizes a nomogram for selecting the most appropriate dosages for maximizing 255 
empirical treatment of Pseudomonas aeruginosa infection and minimizing the risk of overexposure 256 
 with CI ceftazidime in HSCT children with high risk FN according to different classes of eGFR and 257 
BSA. Advisable dosages should be of 4g q24h CI and of 5g q24h CI in six clinical scenarios each. 258 
The highest dose of 6g q24h CI should be advisable only in those patients with the highest classes of  259 
BSA and eGFR. In patients having the lowest BSA estimates (0.30-0.64 m2) and decreased renal 260 
function (eGFR of 50-145 or 145.1-200 mL/min/1.73 m2), advisable ceftazidime dosages should not 261 
exceed 3g q24h CI, but this may allow only suboptimal PTAs (74 and 70%, respectively). However, 262 
a dose increase to 3.5 g q24h by CI may be considered in children with eGFR of 145.1-200 263 
mL/min/1.73 m2, as PTA increases to 85.6%   with a probability of toxicity of only 2.1%. In both 264 
these scenario, the dose of 3g q24h by CI enabled the attainment of  the less aggressive targets of 265 
Css/MIC ≥ 1 and Css/MIC ≥ 2, with PTA > 97.8%.    266 
The CFRs against Pseudomonas aeruginosa achievable in HSCT children with the advisable 267 
CI ceftazidime dosages are summarized in Table 5. Overall, all regimens were associated with CFRs 268 
> 87.1% when considering the EUCAST MIC distribution, and > 79.4% when considering our local  269 
MIC distribution.   CFRs associated with a less aggressive target of Css/MIC ≥ 1 are reported in Table 270 
S3. CFRs were > 96.2% when considering the EUCAST MIC distribution and > 88.1% when 271 
considering our local MIC distribution. The risk-to-benefit ratios for the CFRs that were associated 272 
with the target of a Css/MIC ≥ 4 are provided in Table S4.  273 
  274 
 Discussion  275 
In this study we developed a population pharmacokinetic model for determining the most 276 
advisable dosages of CI ceftazidime for treatment of Pseudomonas aeruginosa in HSCT children 277 
with neutropenia.   278 
The mean estimated CL (3.18 L/h or 0.14 L/h/kg) in our population was comparable to the 279 
values previously observed among hospitalized pediatric patients aged between 6 and 18 years (0.17-280 
0.23 L/h/kg)32 and/or infants aged < 2 years (0.17 L/h/kg).33 V was also consistent with values 281 
reported for patients of similar ages (13.0 – 22.2 L).32 282 
The finding that eGFR was a significant covariate affecting ceftazidime CL is consistent with 283 
a population pharmacokinetic study previously conducted in infants.33 Ceftazidime is predominantly 284 
eliminated via the renal route.  Dosages should be adjusted according to the degree of renal function.  285 
BSA was also a significant covariate of ceftazidime CL in our study population. This finding was not 286 
described previously, and seems biologically plausible, as in children renal weight was found to be 287 
significantly correlated with BSA.34 Interestingly, guidelines on pediatric dosing of hydrophilic drugs 288 
that are renally excreted recommend dose normalization to BSA when children are aged more than 2 289 
years.35   290 
To the best of our knowledge, the pharmacokinetics of CI ceftazidime was previously assessed 291 
only once in FN children with cancer.19 This was an early prospective study carried out among 20 292 
onco-hematologic pediatric patients with FN, with a median age of 5.4 years and mean eGFR of 108 293 
± 18 mL/min/1.73 m2, who were empirically treated with a dose of 200 mg/kg daily. In that study CI 294 
ceftazidime was well tolerated, and the only pharmacokinetic parameter reported was Css, so that we 295 
had no chance to compare our estimates for the pharmacokinetic parameters.  296 
Mortality from Pseudomonas aeruginosa bacteremia remains unacceptably high in children 297 
and adolescents with FN.8  A recent retrospective study conducted among 31 children with FN 298 
showed that appropriate antimicrobial treatment and combination therapy of an antipseudomonal 299 
 beta-lactam with an aminoglycoside was associated with higher survival rates.36  This suggests that 300 
optimized antimicrobial treatment may increase the percentage of favorable clinical outcomes.  301 
Preclinical and clinical studies showed that targeting CI ceftazidime Css at 4 times the MIC 302 
was effective against Pseudomonas aeruginosa infections.18, 37 Our findings suggest that CI 303 
ceftazidime dosages of 4-6 g daily may achieve this pharmacodynamic target in most cases.    304 
It is worth noting that theoretically, when considering a more conservative pharmacodynamic 305 
target of Css /MIC ≥ 1, these dosages could be helpful even when in presence of resistant strains of 306 
Pseudomonas aeruginosa with an MIC up to 32 mg/L.  Interestingly, a similar approach was chosen 307 
in the treatment of an 18-year-old female with a bacteremia caused by a resistant strain of 308 
Pseudomonas aeruginosa with an MIC of 64 mg/L.  It was shown that high-dose CI ceftazidime (9.6 309 
g daily) for 6 consecutive days with a targeted Css of 80-100 mg/L was successful.
18  310 
Our study has some limitations. Its retrospective design with sparse TDM sampling is 311 
probably the most important. The high lambda value used in the error model that implies the presence 312 
of relevant process noise is a another limitation to report. Finally, we were unable to assess the 313 
specific role of ceftazidime in clinical outcome as most of the patients received an antipseudomonal 314 
combination therapy. 315 
In conclusion, our findings suggest that eGFR and BSA are important clinical covariates 316 
affecting the population pharmacokinetics of CI ceftazidime in HSCT children with high risk FN.  317 
Dosages ranging between 4 and 6 g daily, by achieving Css 4-fold higher than the EUCAST clinical 318 
breakpoint of ceftazidime versus P. aeruginosa, may maximize the empirical treatment of P. 319 
aeruginosa infections in most clinical scenarios. TDM may be helpful in appropriately targeting 320 
ceftazidime Css in this patient population.  321 
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 Table 1. Demographic and clinical characteristics of the population. 
Total number of patients 46 
Age (years) 7.5 (4.0 – 12.0) 
Gender (male/female) 29/17 
Weight (kg) 25.0 (14.03 – 39.80) 
Height (m) 1.20 (1.01 – 1.49) 
Body surface area (m2) 0.88 (0.64 – 1.34) 
eGFR (mL/min/1.73 m2) 200.0 (145.0 – 286.0) 
Time from HSCT (days) 6.0 (1.0 – 11.75) 
Type of hematological disease   
 ALL 22 (47.8) 
 AML 5 (10.9) 
 JMML/CML 5 (10.9) 
 Aplastic/Fanconi anemia 4 (8.8) 
 Neuroblastoma 3 (6.5) 
 Congenital immunodeficiency disorders 3 (6.5) 
 Sickle cell anemia 2 (4.3) 
 Ewing sarcoma 2 (4.3) 
Ceftazidime treatment characteristics   
 Dose/kg/day (mg/kg) 145.98 (128.31 – 171.27) 
 Css (mg/L) 49.23 (36.81 – 62.88) 
 No. of TDM instances 1.0 (1.0 – 2.0) 
 Duration of treatment (days) 10.5 (7.0 – 16.0) 
 Additional antibiotics  
  Amikacin 38 (82.6) 
  Teicoplanin 19 (41.3) 
  Vancomycin 14 (30.4) 
  Levofloxacin 13 (28.3) 
  Tigecycline 5 (10.9) 
  Metronidazole 3 (6.5) 
Data for continuous variable are presented as median (IQR) and data for dichotomous variables are 
presented as number (%). ALL, acute lymphocytic leukemia; AML, acute myeloid leukemia; BSI, 
blood stream infections; CML, chronic  myeloid leukemia; Css, ceftazidime steady-state plasma 
concentration; FN, febrile neutropenia; JMML, juvenile myelomonocytic leukemia; HSCT, 
hematopoietic stem cell transplantation. 
437 
  
Table 2. Parameter estimates of ceftazidime for the final covariate two-compartment population pharmacokinetic model. 
 Mean Standard deviation Coefficient of variation (%) Median 
CL (L/h) = θ1 • (
𝐵𝑆𝐴
0.88
)θ2 • (
𝑒𝐺𝐹𝑅
200.5
)θ3 
 θ1 2.83 1.29 45.66 2.71 
 θ 2 0.68 0.37 54.31 0.84 
 θ 3 0.34 0.19 55.79 0.28 
V (L) = θ4 • (
ℎ𝑒𝑖𝑔ℎ𝑡
120
)θ5 
 θ4 33.95 32.09 94.52 25.89 
 θ 5 0.95 0.82 86.02 0.85 
kcp (h-1) 11.51 14.69 127.74 3.70 
kpc (h-1) 15.42 3.56 23.11 14.91 
BSA, body surface area; CL, total clearance of fluconazole; eGFR, estimated glomerular filtration rate;  kcp and kpc, first-order inter-compartmental 
transfer rate constant connecting the central and peripheral compartments; V, volume of distribution of the central compartment.  
 
  
 Table 3. Percentages of probability of causing ceftazidime overexposure (defined as steady-state concentrations [Css] > 100 mg/L) with incremental 
dosages administered by continuous infusion (CI) in HSCT children with high risk febrile neutropenia according to different classes of estimated 
glomerular filtration rate (eGFR) and body surface area (BSA). 
Class of eGFR 
(mL/min/1.73 m2) 
Class of BSA 
(m2) 
Ceftazidime dosages 
(g q24h CI) 
1  2  3  4  5 6  
50.0-145.0 0.30-0.64 0 0.1 3.0 29.4 45.5 48.7 
 0.65-0.88 0 0 0 2.6 14.6 39.1 
 0.89-1.34 0 0 0 0.1 3.6 8.8 
 1.35-1.84 0 0 0 0 0.7 4.9 
        
145.1-200.0 0.30-0.64 0 0 0.5 11.3 36.2 46.6 
 0.65-0.88 0 0 0 0.2 2.1 18.0 
 0.89-1.34 0 0 0 0 0 1.7 
 1.35-1.84 0 0 0 0 0 0.1 
        
200.1-286.0 0.30-0.64 0 0 0 5.0 22.0 38.3 
 0.65-0.88 0 0 0 0.1 0.5 6.4 
 0.89-1.34 0 0 0 0 0 0.3 
 1.35-1.84 0 0 0 0 0 0 
        
286.1-422.0 0.30-0.64 0 0 0 2.2 16 28.1 
 0.65-0.88 0 0 0 0 0.4 2.5 
 0.89-1.34 0 0 0 0 0 0 
 1.35-1.84 0 0 0 0 0 0 
  
 Table 4. Advisable continuous infusion (CI) ceftazidime dosages for maximizing empirical treatment against Pseudomonas aeruginosa (PTA ≥ 
90% of achieving Css/MIC ≥ 4 against the EUCAST clinical breakpoint of 8 mg/L) in HSCT children with high risk FN in relation to different 
classes of estimated glomerular filtration rate (eGFR) and of body surface area (BSA). 
Class of eGFR 
(mL/min/1.73 m2) 
Class of BSA 
(m2) 
0.30-0.64 0.65-0.88 0.89-1.34 1.35-1.84 
50.0-145.0    3 g q24h CI * 4 g q24h CI 4 g q24h CI 5 g q24h CI 
145.1-200.0    3 g q24h CI ° 4 g q24h CI 5 g q24h CI 5 g q24h CI 
200.1-286.0 4 g q24h CI 4 g q24h CI 5 g q24h CI 6 g q24h CI 
286.1-422.0 4 g q24h CI 5 g q24h CI 5 g q24h CI 6 g q24h CI 
Symbols identify suboptimal PTAs: * PTA <75%; ° PTA <70%  
 
  
 Table 5. Cumulative fraction of response with the advisable continuous infusion (CI) ceftazidime dosages targeting  Css/MIC ≥ 4 against 
Pseudomonas aeruginosa in relation to the MIC distribution of EUCAST and that observed at our center in HSCT children with high risk FN in 
relation to different classes of estimated glomerular filtration rate (eGFR) and of body surface area (BSA)  
Class of eGFR 
(mL/min/1.73 m2) 
Class of BSA 
(m2) 
Ceftazidime 
dosages 
CFR (%) 
According to  
EUCAST distribution 
According to  
our local distribution 
50.0-145.0 0.30-0.64 3 g q24h CI 88.3 80.3 
 0.65-0.88 4 g q24h CI 90.2 81.8 
 0.89-1.34 4 g q24h CI 88.3 80.2 
 1.35-1.84 5 g q24h CI 88.9 80.7 
     
145.1-200.0 0.30-0.64 3 g q24h CI 87.1 79.4 
 0.65-0.88 4 g q24h CI 89.1 80.9 
 0.89-1.34 5 g q24h CI 89.2 80.9 
 1.35-1.84 5 g q24h CI 88.5 80.4 
     
200.1-286.0 0.30-0.64 4 g q24h CI 90.1 81.7 
 0.65-0.88 4 g q24h CI 88.2 80.2 
 0.89-1.34 5 g q24h CI 88.7 80.5 
 1.35-1.84 6 g q24h CI 88.8 80.6 
     
286.1-422.0 0.30-0.64 4 g q24h CI 89.4 81.2 
 0.65-0.88 5 g q24h CI 89.9 81.4 
 0.89-1.34 5 g q24h CI 88.3 80.2 
 1.35-1.84 6 g q24h CI 88.0 79.9 
 
   
 Figure Legend 
 
Figure 1. Diagnostic plot for the final covariate model. Observed versus population predicted 
concentrations (left panel) and individual predicted concentrations (right panel) are shown. Solid lines 
refer to linear regression between observed and predicted concentrations.  
 
Figure 2. Probability of target attainment (PTA) of Css/MIC ≥ 4 at the EUCAST clinical breakpoint 
of 8 mg/L versus Pseudomonas aeruginosa with incremental dosages of continuous infusion (CI) 
ceftazidime in relation to different classes of estimated glomerular filtration rate (eGFR) and of body 
surface area (BSA). Horizontal dotted lines identify the threshold for optimal PTA (≥ 90%). 
 
 
 
  
   
  
 
 
  
